Plus the small companies which have hired senior scientists from Bristol-Myers Squibb and Merck Serono.
Pfizer has brought on board diabetes expert Morris Birnbaum who will serve as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research.
Birnbaum previously held the role of Willard Ware Professor of Diabetes and Metabolic Diseases and Associate Dean for Biomedical Core Resources at the Perelman School of Medicine, University of Pennsylvania. He has also been an investigator at the Howard Hughes Medical Institute, the author of more than 200 scientific papers, and elected into the American Association of Clinical Investigation, the American Association of Physicians, and a Fellow of the American Association for the Advancement of Science.
In his new role based in Pfizer’s R&D hub in Massachusetts, Birnbaum will work on clinical programmes for type 2 diabetes, diabetic nephropathy, and hyperlipidemia, said Rod MacKenzie, Group Senior Vice President and Head of PharmaTherapeutics R&D. “He is among the leading contributors to our contemporary understanding of the regulation of intracellular metabolism.”
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions